Revenue
2017
2018
2019
2022
2023
2024
2025
enVVeno Medical Corp (NVNO)
Price$11.05Cached quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | $31,243 | $186,552 | $422,111 |
| Gross profit | — | — | — | — | — | — | — | $186,552 | $2,452 |
| Gross margin | — | — | — | — | — | — | — | 100.00% | 0.58% |
| Research & development | $10.0M | $12.2M | $13.6M | $9.9M | $5.7M | $4.3M | $2.2M | $1.2M | $649,736 |
| Operating expenses | $20.9M | $23.8M | $25.2M | $24.9M | — | — | — | $8.0M | $6.1M |
| Operating income | −$20.9M | −$23.8M | −$25.2M | −$24.9M | −$16.9M | −$9.1M | −$7.7M | −$7.9M | −$6.1M |
| Operating margin | — | — | — | — | — | — | −24,566.50% | −4,210.51% | −1,445.89% |
| EBITDA | −$20.8M | −$23.6M | −$25.0M | −$24.7M | −$16.7M | −$9.0M | −$7.6M | −$7.7M | −$6.0M |
| EBITDA margin | — | — | — | — | — | — | −24,170.70% | −4,138.99% | −1,412.91% |
| Net income | −$19.5M | −$21.8M | −$23.5M | −$24.7M | −$16.5M | −$9.1M | −$7.6M | −$13.0M | −$7.8M |
| Net profit margin | — | — | — | — | — | — | −24,406.74% | −6,991.46% | −1,845.83% |
| Basic EPSper basic share | -$33.06 | -$44.53 | -$66.85 | -$77.00 | -$66.50 | -$263.90 | -$423.50 | -$38,281.25 | -$29,531.25 |
| Diluted EPSper diluted share | -$33.06 | -$44.53 | -$66.85 | -$77.00 | -$66.50 | -$263.90 | -$423.50 | -$38,281.25 | -$29,531.25 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
BERMAN ROBERT ANDREW | 22.24K |
Jenusaitis Matthew | 16.55K |
Gray Robert | 11.16K |
Shrivastava Sanjay | 9.29K |
Duhay Francis | 2.36K |
Glickman Marc H. | 1.6K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 11, 2026Form 4 · 10b5-1 | Duhay FrancisDirector | SellCommon Stock | 140 | $10.31 | $1.4K | 2.4K |
| Mar 12, 2026Form 4 · 10b5-1 | Duhay FrancisDirector | SellCommon Stock | 140 | $11.52 | $1.6K | 2.5K |
| Dec 11, 2025Form 4 · 10b5-1 | Duhay FrancisDirector | SellCommon Stock | 4.9K | $0.36 | $1.8K | 92.5K |
| Sep 15, 2025Form 4 · 10b5-1 | Duhay FrancisDirector | SellCommon Stock | 4.9K | $0.83 | $4.1K | 97.4K |
| Dec 31, 2024Form 4 | Duhay FrancisDirector | BuyCommon Stock | 81.4K | $3.07 | $250.0K | 102.3K |